Valuation
- Market cap
- 6,826,230,000
- Revenue TTM
- $36,130,000
- Net income TTM
- $-215,330,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -595.99%
- Debt to equity
- 0.00
Trading
- Volume
- 2,728,600
- Avg volume
- 1,360,874
- Day's range
- $87.14 – $96.86
- Shares out
- 75,847,000
- Stochastic %K
- 29%
- Beta
- 1.06
- Analysts
- Sell
- Price target
- $97.00
Company profile
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patient...
Show more
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. As of December 11, 2025, Merus N.V. operates as a subsidiary of Genmab A/S.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 31 30 253 8800
- Website
- https://www.merus.nl
- Address
- Uppsalalaan 17, 3rd & 4th floor, Utrecht, Netherlands
Latest news
No headlines yet.
